ALEC Stock Overview
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Alector, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.39 |
| 52 Week High | US$9.07 |
| 52 Week Low | US$3.66 |
| Beta | 0.78 |
| 1 Month Change | -8.49% |
| 3 Month Change | -7.55% |
| 1 Year Change | -27.26% |
| 3 Year Change | -67.03% |
| 5 Year Change | -73.12% |
| Change since IPO | -70.06% |
Recent News & Updates
Recent updates
Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results
Mar 01
The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%
Jan 19Alector: Good Data, Huge Cash, No Near Term Catalyst
Jan 16Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation
Sep 25Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation
Jun 27Analysts Are Betting On Alector, Inc. (NASDAQ:ALEC) With A Big Upgrade This Week
Mar 02Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans
Jan 16Alector: Advancement Of Third Alzheimer's Drug Brings About Huge Potential
Oct 04AbbVie ends partnership with Alector for Alzheimer’s candidate
Jul 08Alector: Potential In Neurology And Cancer Treatments
Jun 14Need To Know: The Consensus Just Cut Its Alector, Inc. (NASDAQ:ALEC) Estimates For 2022
May 18Alector: Expect Phase 3 Data Next Year
Apr 16These Analysts Just Made An Downgrade To Their Alector, Inc. (NASDAQ:ALEC) EPS Forecasts
Feb 27Alector, Inc: A Newer Biotech Company With Big Potential
Jan 26Alector: The GSK Deal Is A Major Value Add
Oct 29We're Not Very Worried About Alector's (NASDAQ:ALEC) Cash Burn Rate
Sep 27This Just In: Analysts Are Boosting Their Alector, Inc. (NASDAQ:ALEC) Outlook for This Year
Aug 05New Forecasts: Here's What Analysts Think The Future Holds For Alector, Inc. (NASDAQ:ALEC)
Jul 06Shareholder Returns
| ALEC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.7% | 4.7% | 0.7% |
| 1Y | -27.3% | 2.7% | 23.9% |
Return vs Industry: ALEC underperformed the US Biotechs industry which returned 2.9% over the past year.
Return vs Market: ALEC underperformed the US Market which returned 24.2% over the past year.
Price Volatility
| ALEC volatility | |
|---|---|
| ALEC Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ALEC's share price has been volatile over the past 3 months.
Volatility Over Time: ALEC's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 244 | Arnon Rosenthal | www.alector.com |
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer’s disease.
Alector, Inc. Fundamentals Summary
| ALEC fundamental statistics | |
|---|---|
| Market cap | US$514.69m |
| Earnings (TTM) | -US$130.39m |
| Revenue (TTM) | US$97.06m |
5.4x
P/S Ratio-4.0x
P/E RatioIs ALEC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALEC income statement (TTM) | |
|---|---|
| Revenue | US$97.06m |
| Cost of Revenue | US$192.12m |
| Gross Profit | -US$95.05m |
| Other Expenses | US$35.34m |
| Earnings | -US$130.39m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.35 |
| Gross Margin | -97.93% |
| Net Profit Margin | -134.34% |
| Debt/Equity Ratio | 0% |
How did ALEC perform over the long term?
See historical performance and comparison